Antiviral oligonucleotides

Details Antiviral oligonucleotides Antiviral oligonucleotides

2011-08-30

2011-08-30

Zara, Jane (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S006120, C435S091100, C435S455000, C435S458000, C536S023100

Reexamination Certificate

active

08008269

ABSTRACT:
Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.

REFERENCES:
patent: 3687808 (1972-08-01), Merigan, Jr. et al.
patent: 4426330 (1984-01-01), Sears
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 4534899 (1985-08-01), Sears
patent: 4615697 (1986-10-01), Robinson
patent: 4806463 (1989-02-01), Goodchild et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5023243 (1991-06-01), Tullis
patent: 5023252 (1991-06-01), Hseih
patent: 5130302 (1992-07-01), Spielvogel et al.
patent: 5177198 (1993-01-01), Spielvogel et al.
patent: 5213804 (1993-05-01), Martin et al.
patent: 5218103 (1993-06-01), Caruthers et al.
patent: 5223618 (1993-06-01), Cook et al.
patent: 5225212 (1993-07-01), Martin et al.
patent: 5248670 (1993-09-01), Draper et al.
patent: 5256775 (1993-10-01), Froehler
patent: 5264221 (1993-11-01), Tagawa et al.
patent: 5264423 (1993-11-01), Cohen et al.
patent: 5264562 (1993-11-01), Matteucci
patent: 5264564 (1993-11-01), Matteucci
patent: 5276019 (1994-01-01), Cohen et al.
patent: 5278302 (1994-01-01), Caruthers et al.
patent: 5356633 (1994-10-01), Woodle et al.
patent: 5366878 (1994-11-01), Pederson et al.
patent: 5378825 (1995-01-01), Cook et al.
patent: 5386023 (1995-01-01), Sanghvi et al.
patent: 5452496 (1995-09-01), Long et al.
patent: 5476925 (1995-12-01), Letsinger et al.
patent: 5489677 (1996-02-01), Sanghvi et al.
patent: 5508270 (1996-04-01), Baxter et al.
patent: 5514788 (1996-05-01), Bennett et al.
patent: 5540935 (1996-07-01), Miyazaki et al.
patent: 5543152 (1996-08-01), Webb et al.
patent: 5556948 (1996-09-01), Tagawa et al.
patent: 5563050 (1996-10-01), Peyman et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5591623 (1997-01-01), Bennett et al.
patent: 5591720 (1997-01-01), Anderson et al.
patent: 5591721 (1997-01-01), Agrawal et al.
patent: 5602244 (1997-02-01), Caruthers et al.
patent: 5610289 (1997-03-01), Cook et al.
patent: 5625050 (1997-04-01), Beaton et al.
patent: 5652355 (1997-07-01), Metelev et al.
patent: 5665710 (1997-09-01), Rahman et al.
patent: 5670634 (1997-09-01), Marotta et al.
patent: 5684148 (1997-11-01), Caruthers et al.
patent: 5695979 (1997-12-01), Caruthers et al.
patent: 5705188 (1998-01-01), Junichi et al.
patent: 5750666 (1998-05-01), Caruthers et al.
patent: 5770713 (1998-06-01), Imbach et al.
patent: 5837449 (1998-11-01), Monia et al.
patent: 5952490 (1999-09-01), Hanecak et al.
patent: 5998602 (1999-12-01), Torrence et al.
patent: 6013240 (2000-01-01), Behr et al.
patent: 6013639 (2000-01-01), Peyman et al.
patent: 6133246 (2000-10-01), McKay et al.
patent: 6143881 (2000-11-01), Metelev et al.
patent: 6153595 (2000-11-01), Draper et al.
patent: 6177246 (2001-01-01), Monia et al.
patent: 6184369 (2001-02-01), Rando et al.
patent: 6262036 (2001-07-01), Arnold et al.
patent: 6316190 (2001-11-01), Rein et al.
patent: 6346614 (2002-02-01), Metelev et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 6573099 (2003-06-01), Graham
patent: 6608035 (2003-08-01), Agrawal et al.
patent: 2003/0119019 (2003-06-01), Winnacker et al.
patent: 2003/0162225 (2003-08-01), James et al.
patent: 2003/0191078 (2003-10-01), Goodchild et al.
patent: 2003/0232435 (2003-12-01), Dobie
patent: 2004/0014957 (2004-01-01), Eldrup et al.
patent: 2004/0242897 (2004-12-01), Guzaev et al.
patent: 2005/0009743 (2005-01-01), Sundquist et al.
patent: 0 339 842 (1989-11-01), None
patent: 0 445 131 (1994-04-01), None
patent: 0 496 813 (1994-12-01), None
patent: WO 90/04384 (1990-05-01), None
patent: WO 91/05545 (1991-05-01), None
patent: WO 92/03051 (1992-03-01), None
patent: WO 93/24510 (1993-12-01), None
patent: WO 94/02499 (1994-02-01), None
patent: WO 94/17093 (1994-08-01), None
patent: WO 94/20073 (1994-09-01), None
patent: WO 94/26764 (1994-11-01), None
patent: WO 96/10391 (1996-04-01), None
patent: WO 96/40062 (1996-12-01), None
patent: WO 97/04787 (1997-02-01), None
patent: WO 97/13499 (1997-04-01), None
patent: WO 97/30731 (1997-08-01), None
patent: WO 98/39352 (1998-09-01), None
patent: WO 99/14226 (1999-03-01), None
patent: WO 99/32619 (1999-07-01), None
patent: WO 01/75164 (2001-10-01), None
patent: WO 02/068582 (2002-09-01), None
patent: WO 03/002903 (2003-01-01), None
patent: WO 03/097661 (2003-11-01), None
patent: WO 2004/002419 (2004-01-01), None
Crooke, S., Ann. Rev. Medicine, vol. 55, pp. 61-95 (2004).
Peracchi et al., Rev. Med. Virol., vol. 14, pp. 47-64 (2004).
Agrawal et al., Molecular Med. Today, vol. 6, pp. 72-81 (2000).
Chirila et al., Biomaterials, vol. 23, pp. 321-342 (2002).
Opalinska et al., Nature Rev., vol. 1, pp. 503-514 (2002).
Trus et al., J. Molec. Biol., vol. 263, pp. 447-462 (1996).
Matsumura, T. et al., Gastroenterology, vol. 137, pp. 673-681 (2009).
Bernstein, D.I. et al., Antimicrobial Agents & Chemotherapy, vol. 52, No. 8, pp. 2727-2733 (2008).
Kocisko, D.S. et al., Antimicrobial Agents & Chemotherapy, vol. 50, No. 3, pp. 1034-1044 (2006).
Lee, A.M. et al., Virology, vol. 372, pp. 107-117 (2008).
Guzman, E.M. et al., Antiviral Therapy, vol. 12, pp. 1147-1156 (2007).
Vaillant, A. et al., Antimicrobial Agents & Chemotherapy, vol. 50, No. 4, pp. 1393-1401 (2006).
Cardin, R.D. et al., Virology J., vol. 6, pp. 214-228 (2009).
Agrawal et al. “Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothiaotes in mice” 1991, Proc. Natl. Acad. Sci. U.S.A. 88: 7595-7599.
Aguilar et al., “Hairpin, Dumbell, and Single-Stranded Phosphodiester . . . ” 1996, Antisense & Nuc. Acid Drug Dev. 6: 157-163.
Beltigner et al., “Binding, Uptake, and Intracellular Trafficking of Phosphorothioate . . . ” 1995, J. Clin. Invest. 95: 1814-1823.
Ceruzzi et al., “Natural and Phosphorothioate-Modified Oligodeoxyribonucleotides Exhibit . . . ” 1990, Nucleosides & Nucleotides 9: 679-695.
Gao et al., “Cellular Pharmacology of Phosphorothioate Oligonucleotides in Human Cells” 1992, Mol. Pharmacol. 43: 45-50.
Gray et al., “Transformed and Immortalized Cellular Uptake of Oligodeoxynucleoside Phosphorothioates . . . ” 1997, Biochem. Pharmacol. 53: 1465-1476.
Iversen et al., “Cellular Uptake and Subcellular Distribution of Phosphorothiaote Oligonucleotides . . . ” 1992, Antisense Res. and Dev. 2: 211-222.
Monteith et al., “Preclinical Evaluation of the Effects of a Novel Antisense Compound . . . ” 1998, Toxicol. Sci. 46: 365-375.
Nestle et al., “Cationic Lipid is Not Required for Uptake and Selective Inhibitory Activity of ICAM-1 Phosphorothioate Antisense . . . ” 1994, J. Invest. Dermatol. 103: 569-575.
Phillips et al., “Pharmacokinetics, Metabolism and Elimination of a 20-mer Phosphorothioate Oligodeoxynucleotide . . . ” 1997, Biochem. Pharmacol. 54: 657-688.
Sajio et al., “Pharmacokinetics, Tissue Distribution, and Stability of Antisense Oligonuceotide Phosphorothioate ISIS 3466 in Mice” 1994, Oncol. Res. 6: 243-249.
Temsamani et al., “Cellular Uptake of Oligodeoxynucleotide Phosphorothioates and Their Analogs” 1994, Antisense Res. and Dev. 4: 35-42.
Thierry et al., “Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides . . . ” 1992, Nuc. Acids Res. 20: 5691-5698.
Wingens et al., “Flow cytometric and microscopic characterization of the uptake and distribution of phosphorothioate . . . ” 1998, Arch. Dermatol. Res. 290: 119-125.
Yu et al., “Comparison of Pharmac

Affiliated with

Also associated with

Rating

Antiviral oligonucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antiviral oligonucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiviral oligonucleotides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2774865